LogicBio Therapeutics, Inc. (LOGC): Price and Financial Metrics
GET POWR RATINGS... FREE!
LOGC POWR Grades
- Growth is the dimension where LOGC ranks best; there it ranks ahead of 48.96% of US stocks.
- LOGC's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
- LOGC's current lowest rank is in the Momentum metric (where it is better than 11.83% of US stocks).
LOGC Stock Summary
- LogicBio Therapeutics Inc's stock had its IPO on October 19, 2018, making it an older stock than merely 6.57% of US equities in our set.
- LOGC's price/sales ratio is 47.01; that's higher than the P/S ratio of 94.28% of US stocks.
- As for revenue growth, note that LOGC's revenue has grown 183.45% over the past 12 months; that beats the revenue growth of 96.4% of US companies in our set.
- Stocks that are quantitatively similar to LOGC, based on their financial statements, market capitalization, and price volatility, are ARDX, LPTX, ABUS, VSTM, and SNES.
- Visit LOGC's SEC page to see the company's official filings. To visit the company's web site, go to www.logicbio.com.
LOGC Valuation Summary
- In comparison to the median Healthcare stock, LOGC's price/sales ratio is 1180.56% higher, now standing at 46.1.
- LOGC's price/sales ratio has moved NA NA over the prior 34 months.
- LOGC's price/sales ratio has moved NA NA over the prior 34 months.
Below are key valuation metrics over time for LOGC.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| LOGC | 2021-07-20 | 46.9 | 2.5 | -4.1 | -2.7 |
| LOGC | 2021-04-16 | 54.5 | 3.1 | -5.8 | -4.3 |
| LOGC | 2020-12-16 | 92.0 | 12.0 | -7.2 | -7.0 |
| LOGC | 2020-12-10 | 80.3 | 10.5 | -6.3 | -6.0 |
| LOGC | 2020-07-01 | 200.6 | 6.1 | -4.9 | -4.2 |
| LOGC | 2019-08-08 | NA | 3.2 | -13.3 | -11.8 |
LOGC Price Target
For more insight on analysts targets of LOGC, see our LOGC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $19.00 | Average Broker Recommendation | 1.33 (Strong Buy) |
LOGC Stock Price Chart Interactive Chart >
LOGC Price/Volume Stats
| Current price | $4.16 | 52-week high | $9.75 |
| Prev. close | $4.17 | 52-week low | $3.72 |
| Day low | $4.16 | Volume | 7,768 |
| Day high | $4.23 | Avg. volume | 157,955 |
| 50-day MA | $4.30 | Dividend yield | N/A |
| 200-day MA | $6.38 | Market Cap | 133.79M |
LogicBio Therapeutics, Inc. (LOGC) Company Bio
LogicBio Therapeutics, Inc. is a genome editing company, which engages in developing medicines to treat rare diseases in patients with significant unmet medical need. It focuses on the commercialization of specific genome editing and integration of the therapeutic transgene. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Cambridge, MA.
Latest LOGC News From Around the Web
Below are the latest news stories about LogicBio Therapeutics Inc that investors may wish to consider to help them evaluate LOGC as an investment opportunity.
What Type Of Shareholders Make Up LogicBio Therapeutics, Inc.'s (NASDAQ:LOGC) Share Registry?Every investor in LogicBio Therapeutics, Inc. ( NASDAQ:LOGC ) should be aware of the most powerful shareholder groups... |
LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that Frederic Chereau, chief executive officer of LogicBio, will participate in a virtual panel discussion entitled "Delivery and Durability of Genetic Medicines" at the William Blair Biotech Focus Conference 2021 on Thursday, July 15, 2021 at 10:00 a.m. ET. |
Is LogicBio Therapeutics, Inc. (LOGC) A Good Stock To Buy?In this article we will analyze whether LogicBio Therapeutics, Inc. (NASDAQ:LOGC) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There’s no better way to get these firms’ immense resources and analytical capabilities working for us than to follow their lead […] |
LogicBio Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1/2 SUNRISE Clinical Trial for the Treatment of Pediatric Patients Suffering from Methylmalonic AcidemiaLogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that the first patient has been dosed with LB-001, the Company's investigational single-administration gene editing therapy based on its proprietary GeneRide™ platform, in the SUNRISE Phase 1/2 clinical trial in pediatric patients with methylmalonic acidemia (MMA). The child re |
LogicBio Therapeutics to Participate in Upcoming Investor ConferencesLogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced that Frederic Chereau, chief executive officer of LogicBio, will participate in virtual fireside chats at the following upcoming investor conferences: |
LOGC Price Returns
| 1-mo | -3.70% |
| 3-mo | -17.62% |
| 6-mo | -49.94% |
| 1-year | -46.94% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -45.48% |
| 2020 | 5.97% |
| 2019 | -30.77% |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...